Common painkiller may prevent pancreatitis after bile duct procedure
NCT ID NCT07661498
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether a single dose of rectal indomethacin, a common anti-inflammatory drug, can prevent pancreatitis in patients undergoing a bile duct procedure (ERCP) who have had a prior sphincterotomy. About 860 adults will be randomly assigned to receive the drug or no drug before the procedure. The study aims to see if this simple preventive measure reduces the risk of post-procedure pancreatitis in this specific group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
indomethacin (rectal suppository)
What this could lead to
If effective, this could provide a simple, low-cost way to prevent pancreatitis after ERCP in patients who have had a prior sphincterotomy.
What could go wrong
This is a phase 4 trial in a specific, lower-risk population, so results may not apply broadly. The drug may not show significant benefit over no treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
San Francisco, California, 94158, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Email: •••••@•••••